Background
==========

Breast cancer, one of the most common cancers, has shown a steady increase in incidence worldwide in recent years. It remains the major cause of cancer-related mortality among women.[@b1-tcrm-12-763],[@b2-tcrm-12-763] According to earlier reports, there are \~1.15 million breast cancer patients diagnosed every year, and the highest incidence of breast cancer is found in Europe and USA.[@b3-tcrm-12-763],[@b4-tcrm-12-763] In the People's Republic of China, the incidence of breast cancer has been growing rapidly. Patients with breast cancer, meanwhile, tend to be younger.[@b5-tcrm-12-763],[@b6-tcrm-12-763] Its pathogenesis is still unclear, although some studies have shown that breast cancer is caused by environmental and genetic factors.[@b7-tcrm-12-763],[@b8-tcrm-12-763]

As a vital Phase II isoenzyme, the glutathione *S*-transferase (GST) family can identify environmentally hazardous materials and regulate the level of other enzymes and proteins in the cell. Thus, it plays an important role in many basic physiological processes of the human body.[@b9-tcrm-12-763]--[@b11-tcrm-12-763] According to their distinct isoelectric points, human GSTs can be divided into seven classes, alpha (α), mu (μ), omega (ω), pi (π), sigma (σ), theta (θ), and zeta (ς). There are also microsomal GST isoenzymes.[@b12-tcrm-12-763] It is reported that there are at least three genes of them with common functional polymorphisms, which are GSTT1 (θ), GSTM1 (μ), and GSTP1 (π). Every mutation in each of them may potentially lead to a loss of enzymatic function.[@b13-tcrm-12-763],[@b14-tcrm-12-763] Many researchers have shown that GSTs are crucial to cellular protection from a great deal of damage, and the polymorphism of GSTs could result in cancers of the esophagus,[@b15-tcrm-12-763] kidney,[@b16-tcrm-12-763] and liver,[@b17-tcrm-12-763] and glioma.[@b18-tcrm-12-763]

A large number of studies have indicated that the GSTT1, GSTM1, and GSTP1 (rs1695) polymorphisms are associated with breast cancer.[@b8-tcrm-12-763],[@b11-tcrm-12-763]--[@b38-tcrm-12-763] However, the results of these studies are inconclusive. Therefore, we performed this meta-analysis of published case--control studies to solve the conflicting results and draw a relatively reliable conclusion.

Materials and methods
=====================

Literature search
-----------------

All related studies published before May 31, 2015, were identified independently by two reviewers through a computer-based search of PubMed ([www.ncbi.nlm.nih.gov/pubmed](http://www.ncbi.nlm.nih.gov/pubmed)) and Web of Knowledge (<http://isiknowledge.com/>) databases. The search terms used in this study were as follows: ("glutathione *S*-transferase" OR "GST" OR "GSTT1" OR "GSTM1" OR "GSTP1") AND ("breast cancer" OR "breast neoplasm" OR "breast carcinoma") AND "polymorphism". There was no language restriction. For this meta-analysis, the included studies had to meet the following criteria: 1) a case--control study on the polymorphism of GSTT1, GSTM1, or GSTP1 polymorphism and the risk of breast cancer; 2) reported genotype frequencies of cases and controls; and 3) the genotypes of control subjects in accordance with the Hardy--Weinberg equilibrium (HWE).

Data extraction
---------------

Two investigators extracted carefully the relevant information independently, and any discrepancy was settled by consensus. The following data were extracted from articles: first author's name, year, country, ethnicity, the source of controls, and the genotype attribution of cases and controls.

Statistical analysis
--------------------

The odds ratio (OR) and their 95% confidence interval (CI) were adopted to evaluate the strength of association between the polymorphism of GSTT1, GSTM1, and GSTP1 (rs1695) and the risk of breast cancer. First, we examined GSTT1 and GSTM1 genotypes using the null vs present model. Then, the relationship between the GSTP1 (rs1695) polymorphism and risk of breast cancer was estimated with allelic (V vs I) model, the recessive (VV vs II + VI), the dominant (VV + VI vs II), and the codominant (VV vs II). The statistical significance of the pooled OR was determined by the *Z*-test, and a *P*\<0.05 was considered statistically significant. HWE was estimated using the chi-squared test among controls, where *P*\<0.05 was considered a significant departure from HWE. We evaluated heterogeneity among included studies with chi-squared-based *Q*-test and *I*^2^ statistic. If the heterogeneity was obvious, with *P*\<0.1, random-effects model was used to calculate the pooled OR; otherwise, the fixed-effects models were adopted. Moreover, subgroup analysis was conducted by ethnicity.

We performed sensitivity analysis by omitting single study every time to assess the robustness of the results. Funnel plots and Egger's tests were used to explore the potential publication bias; *P*\>0.05 was considered to indicate no significant publication bias. All *P*-values were based on two-sided tests.

Results
=======

Study characteristics
---------------------

Our meta-analysis was conducted according to guidelines of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) statement (checklist)[@b39-tcrm-12-763] and "Meta-analysis on Genetic Association Studies" statement (checklist).[@b40-tcrm-12-763] The flowchart is illustrated in [Figure 1](#f1-tcrm-12-763){ref-type="fig"}. A total of 171 potentially relevant articles were found by the literature search, and among these 121 articles were excluded because of obvious irrelevance after a preliminary screening of the titles and abstracts. In addition, after full-text reviews of the remaining 33 articles, 14 articles were excluded for the following reasons: articles were based on studies on prognosis or chemotherapy sensitivity (n=9), article was a quantitative analysis (n=1), article was a case report (n=1), articles had insufficient data (n=3), and studies deviated from HWE (n=2). Articles reporting data for different kinds of GST ethnicity were treated as independent studies. Finally, 19 articles[@b8-tcrm-12-763],[@b19-tcrm-12-763]--[@b36-tcrm-12-763] involving 41 independent case--control studies with 10,067 cancer cases and 12,276 controls completely met the inclusion criteria. The detailed data collected from the included studies are summarized in [Table 1](#t1-tcrm-12-763){ref-type="table"}.

Association of GSTM1-null polymorphism with breast cancer risk
--------------------------------------------------------------

Seventeen studies including 4,046 cases and 5,344 controls studied the association between GSTM1-null polymorphism and breast cancer.[@b8-tcrm-12-763],[@b19-tcrm-12-763],[@b21-tcrm-12-763]--[@b26-tcrm-12-763],[@b28-tcrm-12-763],[@b30-tcrm-12-763]--[@b31-tcrm-12-763],[@b33-tcrm-12-763]--[@b36-tcrm-12-763] Our meta-analysis showed that there was no significant association of GSTM1-null polymorphism with breast cancer risk (OR =1.13, 95% CI =0.97--1.32) ([Table 2](#t2-tcrm-12-763){ref-type="table"}). When stratifying for ethnicity, we found that GSTM1-null polymorphism could increase the breast cancer risk for Asians (OR =1.17, 95% CI =1.04--1.32) ([Figure 2](#f2-tcrm-12-763){ref-type="fig"}). However, no significant association was found for Caucasians (OR =1.13, 95% CI =0.85--1.52) or mixed ethnicity (OR =0.90, 95% CI =0.62--1.30) ([Table 2](#t2-tcrm-12-763){ref-type="table"}).

Association of GSTT1-null polymorphism with breast cancer risk
--------------------------------------------------------------

Fourteen studies including 2,788 cases and 3,686 controls studied the association of GSTT1-null polymorphism with breast cancer.[@b8-tcrm-12-763],[@b19-tcrm-12-763],[@b21-tcrm-12-763]--[@b23-tcrm-12-763],[@b25-tcrm-12-763],[@b28-tcrm-12-763],[@b30-tcrm-12-763]--[@b31-tcrm-12-763],[@b34-tcrm-12-763]--[@b36-tcrm-12-763] Totally, our meta-analysis showed that there was no significant association between GSTT1-null polymorphism and the risk of breast cancer (OR =1.15, 95% CI =0.93--1.42) ([Table 2](#t2-tcrm-12-763){ref-type="table"}). When stratifying for ethnicity, similarly, we found that GSTT1-null polymorphism could increase breast cancer risk among Asians (OR =1.19, 95% CI =1.01--1.41) ([Figure 3](#f3-tcrm-12-763){ref-type="fig"}). However, we found that there was no significant association of GSTT1-null polymorphism with breast cancer risk for Caucasians (OR =1.17, 95% CI =0.96--1.42) or mixed ethnicity (OR =0.88, 95% CI =0.57--1.34) ([Table 2](#t2-tcrm-12-763){ref-type="table"}).

Association of GSTP1 Val105Ile polymorphism with breast cancer risk
-------------------------------------------------------------------

Ten studies including 3,233 cases and 3,246 controls studied the association between GSTP1 Val105Ile (rs1695) polymorphism and breast cancer.[@b20-tcrm-12-763],[@b23-tcrm-12-763]--[@b24-tcrm-12-763],[@b27-tcrm-12-763],[@b29-tcrm-12-763]--[@b32-tcrm-12-763],[@b34-tcrm-12-763],[@b36-tcrm-12-763] In the allelic model, our meta-analysis showed that GSTP1 Val105Ile (rs1695) polymorphism was not associated with breast cancer risk overall (OR =1.21, 95% CI =0.99--1.48) ([Table 2](#t2-tcrm-12-763){ref-type="table"}). When stratifying for ethnicity, similarly, we found that GSTP1 Val105Ile polymorphism could increase breast cancer risk for Caucasians (OR =1.16, 95% CI =1.01--1.34) ([Figure 4](#f4-tcrm-12-763){ref-type="fig"}). However, we found that there was no significant association between GSTP1 Val105Ile (rs1695) polymorphism and breast cancer risk for Asians (OR =1.26, 95% CI =0.91--1.75) ([Table 2](#t2-tcrm-12-763){ref-type="table"}).

In the recessive model, we found that GSTP1 Val105Ile (rs1695) polymorphism was not associated with breast cancer risk overall (OR =1.16, 95% CI =0.83--1.62) ([Table 2](#t2-tcrm-12-763){ref-type="table"}). When stratifying for ethnicity, we found that GSTP1 Val105Ile (rs1695) polymorphism had no significant association with the risk of breast cancer for Caucasians (OR =1.14, 95% CI =0.86--1.52) ([Table 2](#t2-tcrm-12-763){ref-type="table"}) or for Asians (OR =1.28, 95% CI =0.70--2.35) ([Table 2](#t2-tcrm-12-763){ref-type="table"}).

Similarly, we did not find any significant association of GSTP1 Val105Ile (rs1695) polymorphism with breast cancer risk overall (OR =1.19, 95% CI =0.93--1.52) and for Caucasians (OR =1.03, 95% CI =0.85--1.25) or Asians (OR =1.34, 95% CI =0.94--1.93) ([Table 2](#t2-tcrm-12-763){ref-type="table"}) in the dominant model.

In codominant model, we found that there was no significant association of GSTP1 Val105Ile (rs1695) polymorphism with breast cancer risk overall (OR =1.24, 95% CI =0.81--1.89) and for Caucasians (OR =1.14, 95% CI =0.84--1.57) or Asians (OR =1.45, 95% CI =0.69--3.05) ([Table 2](#t2-tcrm-12-763){ref-type="table"}).

Sensitivity analysis
--------------------

A single study was excluded each time to reflect the effect of an individual study on the pooled OR and 95% CI. The deletion of any single study did not qualitatively alter the corresponding pooled ORs; these findings confirmed the stability of our meta-analysis results (data not shown).

Publication bias
----------------

We performed both Begg's and Egger's tests and generated a funnel plot to evaluate any potential publication bias. The symmetry of the funnel plots indicated no statistical evidence of publication bias in this meta-analysis (data not shown).

Discussion
==========

Large-scale epidemiological studies on gene polymorphisms can contribute to uncovering the role and the corresponding mechanism of genes in the development of many diseases. To the best of our knowledge, this is the most comprehensive meta-analysis that evaluated the association of GSTM1-null, GSTT1-null, and GSTP1 Val105Ile (rs1695) polymorphisms with the risk of breast cancer. The obvious strength of meta-analysis is based on the accumulation of published data, providing a greater amount of information to find significant differences. In total, the meta-analysis involved 41 independent case--control studies of 19 articles comprising 10,067 cancer cases and 12,276 controls.

Our results demonstrate that the GSTM1-null, GSTT1-null, and GSTP1 Val105Ile (rs1695) polymorphisms are not significantly associated with breast cancer risk in the overall populations. However, in the stratified analysis by ethnicity, significant associations were found in Asians for GSTM1-null and GSTT1-null polymorphisms. Significant result was also obtained for GSTP1 Val105Ile (rs1695) polymorphism among Caucasians. However, no significant associations were found among Caucasian and mixed populations for GSTM1-null and GSTT1-null polymorphism. Similarly, no significant associations were found among Asians for GSTP1 Val105Ile (rs1695) polymorphism.

In 2013, Liu et al[@b37-tcrm-12-763] performed a meta-analysis, which showed that GSTP1 Val105Ile (rs1695) polymorphism was associated with the susceptibility of breast cancer in Asians under the allelic and recessive model. In another meta-analysis study, the *GSTM1* and *GSTP1* polymorphisms (under allelic and dominant model) were found to be associated with increased breast cancer risk Asian population, especially in East Asians, and that the *GSTT1* polymorphism might not be associated with breast cancer.[@b38-tcrm-12-763] These differences between different meta-analyses might have been due to the relatively small number of samples in each study.

There are several possible causes for the differences between different ethnicities. First of all, the frequencies of the genotype vary sharply between different ethnicities. For instance, the homozygous null genotype distributions of the GSTT1 polymorphism change greatly between Asian and Caucasian populations, with a prevalence of 79.6% and 19.0%, respectively.[@b23-tcrm-12-763],[@b41-tcrm-12-763] Therefore, more studies with larger sample sizes are needed to further confirm ethnic difference in the association between these polymorphisms and breast cancer risk. Second, different lifestyles may explain partially the ethnic difference, as Asians and Caucasian adopt different food preferences. Previous studies have demonstrated that high intake of certain fruits, vegetables, milk, and eggs may have important effects on breast cancer risk.[@b42-tcrm-12-763]--[@b44-tcrm-12-763] Different lifestyles, such as maintaining body mass index, physical exercise, and intake of sugary drinks, red meat, and alcohol, also have important influence in breast cancer susceptibility.[@b45-tcrm-12-763],[@b46-tcrm-12-763] Finally, the finding of an increasing breast cancer risk only in Asians is a chance of finding because of the relatively small number of the studies among each ethnicity included in this meta-analysis.

GSTs are important Phase II detoxification enzymes involved in the metabolism of a large number of potential carcinogens. Mutations in all of the three GST genes may lead to oxidative stress and the accumulation of reactive quinone intermediates in cells. In the GST family, it is well known that the proteins GSTM1, GSTT1, and GSTP1 (rs1695) have important influence on the modification of some vital enzymes. Many studies have shown that these enzymes may combine with glutathione and affect the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins, and products of oxidative stress.[@b47-tcrm-12-763],[@b48-tcrm-12-763]

Limitations
===========

Several limitations of our study should be acknowledged when interpreting the results. First, due to the failure in acquiring detailed original information, all the results of this meta-analysis is based on single-factor calculation without adjustment by other important co-variables, such as menopausal state, age of menarche, tobacco smoking habit, lifestyle factors, and family history. Second, some heterogeneity was observed in this study due to uncontrolled confounding factors and selection bias. We solved this problem by adopting a random-effects model and performing sensitivity analysis. Third, only articles published and written in English were included this meta-analysis, which might have resulted in some degree of publication bias. However, no significant publication bias was detected, indicating that no noticeable harm was done by potential publication bias.

Conclusion
==========

Our meta-analysis demonstrates that GSTM1- and GSTT1-null polymorphisms can increase breast cancer risk for Asians, and GSTP1 Val105Ile (rs1695) polymorphism can increase breast cancer risk for Caucasians.
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**Abbreviations:** GSTT1, glutathione *S*-transferase T1; OR, odds ratio; CI, confidence interval.](tcrm-12-763Fig3){#f3-tcrm-12-763}
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###### 

Characteristics of the literature included in the meta-analysis

  First author                          Year   Country                      Ethnicity   Sample size (cases/controls)   GSTM1   GSTT1   GSTP1   *P*~HWE~                                                             
  ------------------------------------- ------ ---------------------------- ----------- ------------------------------ ------- ------- ------- ---------- ----- ----- ----- ----- ----- ----- ---- ----- ----- ---- -------
  Bailey et al[@b19-tcrm-12-763]        1998   USA                          Caucasian   164/162                        91      73      100     62         47    117   44    118   --    --    --   --    --    --   
  Bailey et al[@b19-tcrm-12-763]        1998   USA                          Mixed       59/59                          20      39      24      35         12    47    17    42    --    --    --   --    --    --   
  Zhao et al[@b20-tcrm-12-763]          2001   USA                          Caucasian   155/332                        --      --      --      --         --    --    --    --    87    58    10   170   133   29   1.000
  Amorim et al[@b21-tcrm-12-763]        2002   Brazil                       Caucasian   79/123                         33      46      65      58         15    64    31    92    --    --    --   --    --    --   
  Amorim et al[@b21-tcrm-12-763]        2002   Brazil                       Mixed       128/256                        50      78      103     153        32    96    65    191   --    --    --   --    --    --   
  Sohail et al[@b22-tcrm-12-763]        2013   Pakistan                     Asian       100/102                        43      57      45      57         27    73    32    70    --    --    --   --    --    --   
  Zgheib et al[@b23-tcrm-12-763]        2013   Lebanon                      Asian       227/98                         111     115     47      51         43    183   20    78    117   94    16   49    39    10   0.74
  Sakoda et al[@b24-tcrm-12-763]        2008   People's Republic of China   Asian       615/878                        321     294     428     450        --    --    --    --    378   215   20   569   277   30   0.15
  Chang et al[@b25-tcrm-12-763]         2006   People's Republic of China   Asian       189/421                        107     82      227     193        111   78    210   210   123   53    13   288   114   19   0.1
  Ambrosone et al[@b26-tcrm-12-763]     1999   USA                          Caucasian   282/343                        145     137     172     171        --    --    --    --    --    --    --   --    --    --   
  Saxena et al[@b27-tcrm-12-763]        2012   India                        Asian       215/215                        --      --      --      --         --    --    --    --    81    89    45   101   75    39   0
  Syamala et al[@b28-tcrm-12-763]       2007   India                        Asian       347/250                        119     228     63      187        56    291   23    227   186   140   21   125   109   16   0.28
  Mohamad[@b29-tcrm-12-763]             2014   Saudi Arabia                 Asian       100/48                         --      --      --      --         --    --    --    --    58    40    2    28    18    2    1.000
  Van Emburgh et al[@b30-tcrm-12-763]   2008   USA                          Caucasian   391/466                        206     185     268     198        69    322   82    384   160   183   42   179   179   35   0.35
  Rangel et al[@b31-tcrm-12-763]        2015   Mexico                       Caucasian   243/118                        117     124     34      79         32    211   22    92    58    105   79   35    53    30   0.27
  Ge et al[@b32-tcrm-12-763]            2013   People's Republic of China   Asian       920/783                        --      --      --      --         --    --    --    --    540   325   55   519   230   34   0.2
  Luo et al[@b8-tcrm-12-763]            2012   People's Republic of China   Asian       353/701                        207     146     414     286        186   167   364   337   --    --    --   --    --    --   
  Christine et al[@b33-tcrm-12-763]     1998   French                       Caucasian   361/437                        201     160     224     213        --    --    --    --    --    --    --   --    --    --   
  Hashemi et al[@b34-tcrm-12-763]       2012   Iran                         Asian       134/152                        86      48      71      81         18    116   12    140   36    72    26   97    52    3    0.29
  Zheng et al[@b35-tcrm-12-763]         2002   USA                          Caucasian   273/657                        100     102     249     232        39    113   62    263   --    --    --   --    --    --   
  Ramalhinho et al[@b36-tcrm-12-763]    2012   Portugal                     Caucasian   101/121                        66      35      45      76         47    54    24    97    54    35    12   55    48    16   0.31

**Abbreviations:** GST, glutathione *S*-transferase; Ile, isoleucine; Val, valine; "--", no data; HWE, Hardy--Weinberg equilibrium.

###### 

Meta-analysis of the association between GSTM1, GSTT1, and GSTP1 polymorphisms and breast cancer risk

  Comparisons      Odds ratio   95% CI       *P*-value   Heterogeneity   Effects model   
  ---------------- ------------ ------------ ----------- --------------- --------------- --------
  GSTM1                                                                                  
   Overall         1.13         0.97--1.32   0.019       66.00           \<0.001         Random
   Caucasian       1.13         0.85--1.52   0.398       79.50           \<.001          Random
   Asian           1.17         1.04--1.32   0.012       41.40           0.115           Fixed
   Mixed           0.9          0.62--1.30   0.567       0.00            0.584           Fixed
  GSTT1                                                                                  
   Overall         1.15         0.93--1.42   0.189       60.00           0.002           Random
   Caucasian       1.17         0.96--1.42   0.127       76.40           0.001           Random
   Asian           1.19         1.01--1.41   0.039       43.30           0.117           Fixed
   Mixed           0.88         0.57--1.34   0.544       0.00            0.378           Fixed
  GSTP1                                                                                  
   V vs I                                                                                
    Overall        1.21         0.99--1.48   0.066       81.30           \<0.001         Random
    Caucasian      1.16         1.01--1.34   0.042       25.40           0.259           Fixed
    Asian          1.26         0.91--1.75   0.159       88.60           \<0.001         Random
   VV vs VV + VI                                                                         
    Overall        1.16         0.83--1.62   0.38        57.40           0.012           Random
    Caucasian      1.14         0.86--1.52   0.355       0.00            0.42            Fixed
    Asian          1.28         0.70--2.35   0.429       73.00           0.002           Random
   VV + VI vs II                                                                         
    Overall        1.19         0.93--1.52   0.159       79.10           \<0.001         Random
    Caucasian      1.03         0.85--1.25   0.76        35.70           0.198           Fixed
    Asian          1.34         0.94--1.93   0.11        85.80           \<0.001         Random
   VV vs II                                                                              
    Overall        1.24         0.81--1.89   0.32        71.10           \<0.001         Random
    Caucasian      1.14         0.84--1.57   0.388       30.40           0.23            Fixed
    Asian          1.45         0.69--3.05   0.324       81.30           \<0.001         Random

**Abbreviations:** GST, glutathione *S*-transferase; CI, confidence interval; I, Ile; Ile, isoleucine; V, Val; Val, valine.
